Massimo Breccia

152PUBLICATIONS
270CO-AUTHORS
Molecular targetsPredictive and prognostic markersOrthopticsMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (152)

|Jun 26, 2026
Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free Remission.

|Jun 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

|Jun 08, 2026
Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

|Apr 23, 2026
ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

|Mar 25, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Paola Guglielmelli, Massimo Breccia, Francesco Mendicino

Pageof 26

Frequent Collaborators

33 joint publications

Mario Tiribelli

31 joint publications

Alessandra Iurlo

28 joint publications

Francesca Palandri

27 joint publications

Elisabetta Abruzzese